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matched the standard dose of gemcitabine (1,000 mg/m2) 
and cisplatin (25 mg/m2) on days 1 and 8, every 3 weeks 
for up to 24 weeks. The dose limiting toxicities (DlTs) 
were determined during the first 6 weeks, and a 3+3 dose 
finding design with cohorts of 3–6 patients was used. Fur-
ther cohort expansion took place.
Results One DlT, namely grade 4 neutropenia, was 
observed among six patients at the starting dosages. Then, 
we expanded the cohort with a total of eighteen patients to 
evaluate rD and no further DlTs were observed. During 
the entire study, the most common grade 3/4 adverse events 
were neutropenia (94 %) and leucopenia (56 %). non-
hematological toxicities were manageable.
Abstract 
Purpose We conducted a phase I study to determine the 
maximum tolerated dose and recommended dose (rD) of 
this gemcitabine plus cisplatin (GC) combination in the 
adjuvant setting for biliary tract cancer (BTC). GC has 
become a standard chemotherapy regimen for patients with 
locally advanced or metastatic BTC; however, the benefit 
of adjuvant therapy for BTC is unclear.
Methods Patients with BTC were eligible if they met 
the following criteria: Stage IB or higher; and undergoing 
resection without major hepatectomy. The starting dose 
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Conclusions We defined the standard dose of GC as the 
rD for adjuvant chemotherapy for BTC treated by curative 
resection without major hepatectomy. Further study is war-
ranted to clarify the safety and efficacy of this regimen for 
all patients.
Keywords Gemcitabine and cisplatin · adjuvant 
chemotherapy · Biliary tract cancer · Phase I
Introduction
Biliary tract cancer (BTC) includes intrahepatic cholangio-
carcinoma, extrahepatic cholangiocarcinoma, gallbladder 
cancer and ampullary cancer. although the incidence rates 
of BTC are relatively low in the USa and some western 
european countries, the rates are high in asia, latin amer-
ica and eastern european countries [1]. There were almost 
18,000 deaths in Japan and 3,200 deaths in the USa from 
extra-hepatic bile duct cancer, ampullary cancer and gall-
bladder cancer [2, 3]. The prognosis of BTC patients is 
extremely poor, with five-year survival rates in the range 
of 5–15 % [4, 5]. even though surgical resection is the only 
curative treatment, the reported overall survival rate follow-
ing surgery is nevertheless only about 40 % [6]. To improve 
the prognosis of BTC requires the development of effective 
adjuvant or neoadjuvant treatment with multidisciplinary 
care.
To date, only two randomized control trials (rCTs) of 
adjuvant chemotherapy for BTC have been reported, but 
both included patients with BTC in limited locations. These 
studies showed no significant benefit from adjuvant chem-
otherapy. Takada et al. [7] reported the results of postop-
erative adjuvant chemotherapy in patients with pancreatic 
cancer and limited BTC, but an intention-to-treat analysis 
showed no significant difference in five-year survival. The 
eSPaC-3 trial was a multicenter rCT of adjuvant chemo-
therapy versus observation with periampullary adenocarci-
noma. although multivariable analysis with adjustment for 
prognostic variables demonstrated a statistically significant 
survival benefit associated with adjuvant chemotherapy, 
median survival time from the primary analysis in the 
chemotherapy group did not significantly differ from that in 
the observation group [8].
In another study, a meta-analysis found a non-signifi-
cant improvement in overall survival with adjuvant therapy 
(chemotherapy, radiotherapy or chemoradiotherapy) com-
pared with surgery alone for BTC, but patients with node-
positive and r1 disease had a significant survival benefit 
[9]. The authors accordingly reported that adjuvant therapy 
is the standard of care for high-risk patients. However, 
this meta-analysis had limitations, included selection bias, 
stage migration and heterogeneous treatments and should 
not be considered conclusive, thereby warranting additional 
prospective studies [10]. Thus, an effective evidence-based 
adjuvant chemotherapy has yet to be identified, as reflected 
by guidelines of the national Comprehensive Cancer net-
work [11] and from guidelines in Japan [12] which strongly 
endorse the need for clinical trials of adjuvant chemother-
apy for patients with resectable BTC.
at this point, however, a standard adjuvant chemo-
therapy for BTC has not been determined. It is necessary 
to develop more effective adjuvant chemotherapy to sup-
press recurrences after surgery. We speculated that com-
bination therapy with gemcitabine plus cisplatin (GC) 
would be an effective and intensive adjuvant chemother-
apy, because in patients with locally advanced or meta-
static BTC, the aBC-02 trial showed a significant sur-
vival advantage for GC over gemcitabine alone [13], and 
similar results were observed in Japan [14]. Therefore, 
we conducted a phase I study to determine the maximum 
tolerated dose (MTD) and recommended dose (rD) of 




Patients with BTC who met the following criteria were 
eligible: histologically confirmed BTC (intrahepatic or 
extrahepatic cholangiocarcinoma, gallbladder cancer 
or ampullary cancer); Stage IB disease or higher; com-
plete macroscopic (r0 or r1) resection without major 
hepatectomy (resection of more than three segments 
defined according to Couinaud’s classification); age 
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performance status of 0–1; adequate marrow function 
(neutrophil count ≥1,500/mm3, platelet count ≥100,000/
mm3); adequate liver function [total serum bilirubin ≤3 
times the upper limit of normal (Uln); aspartate ami-
notransferase and alanine aminotransferase levels ≤5 
times the Uln]; adequate renal function (serum creati-
nine concentration ≤1.2 mg/dl and creatinine clearance 
≥50 ml/min); adequate oral intake; and written informed 
consent. Patients satisfying these criteria started the reg-
imen within 4–12 weeks after surgical resection. exclu-
sion criteria were the presence of pulmonary fibrosis or 
interstitial pneumonia, severe heart disease, uncontrolled 
diabetes mellitus, and active infection; pregnancy or lac-
tation; women of childbearing age, unless using effec-
tive contraception; severe drug hypersensitivity; mental 
disorder; concurrent double cancer; and other serious 
medical conditions. The study protocol was approved 
by the institutional review board of each participating 
institution.
Study design
This phase I study (ClinicalTrials.gov ID nCT01297998; 
UMIn ID 000004622) was designed by the Kansai Hepa-
tobiliary Oncology Group (KHBO). Patient registration and 
data management were conducted at an independent data 
center at the Osaka Medical Center for Cancer and Cardio-
vascular Diseases. all laboratory tests required to assess 
eligibility were completed within 14 days before the start 
of protocol treatment. Planned dosages of gemcitabine 
(mg/m2)/cisplatin (mg/m2) were as follows for 6 months. 
level 1 (starting level): 1,000/25 on day 1 and 8, every 
3 weeks. level 0: 800/25 on day 1 and 8, every 3 weeks. 
level-1: 1,000/25 on day 1, every 2 weeks. level-2: 800/25 
on day 1, every 2 weeks.
Definition of DlTs, MTD and rD
Dose limiting toxicities (DlTs) were determined during 
the first 6 weeks. DlT was defined according to Com-
mon Toxicity Criteria adverse events v4.0 (CTCae 
v4.0) as one or more of the following events: (1) grade 4 
leucopenia, neutropenia or thrombocytopenia, (2) grade 
3–4 neutropenia complicated by fever, (3) clinically 
significant grade 3–4 non-hematological toxicities, (4) 
need to withhold GC on day 8 consecutively in the first 
6 weeks due to an adverse event or (5) delay in course 
of more than 14 days following an adverse event. If 
DlT was observed in one or two of three patients, three 
additional patients were enrolled at that level. If three or 
more of six patients or if all three initial patients expe-
rienced DlT at that level, the dose was de-escalated to 
the next lower level. MTD was defined as the lowest 
dose level that produced DlTs in three or more of six 
patients or in all three initial patients. rD was defined 
as one dose level lower than the MTD, considering the 
toxicity and tolerability observed in the entire study. If a 
DlT was observed in one or two of six patients in level 
1 (starting dose), level 1 was initially defined as the 
rD. The protocol required the enrollment of additional 
patients to examine the safety of the rD according to the 
recommendation from the Data and Safety Monitoring 
Committee (DSMC). There was no dose escalation in 
individual patients.
Treatment
Chemotherapy was started and repeated on day 1 if abso-
lute neutrophil count was ≥1,000/mm3; platelet count 
was ≥100,000/mm3; total bilirubin was ≤3 times the 
Uln; aST/alT was ≤five times the Uln; creatinine 
was ≤1.2 mg/dl; and any non-hematological toxicities 
were ≤grade 1. If the patient did not meet the above cri-
teria, chemotherapy was delayed by 1 week or more until 
recovery. On day 8, chemotherapy was started and repeated 
if absolute neutrophil count was ≤1,000/mm3; platelet 
count was ≤70,000/mm3; creatinine was ≤1.5 mg/dl; and 
any non-hematological toxicities were ≤grade 1. GC dose 
was reduced to −1 level if an adverse event defined as a 
DlT occurred. The protocol allowed a single dose reduc-
tion only, and no re-escalation was allowed. Protocol treat-
ment was discontinued in individual patients if any of the 
following occurred: completion of protocol treatment for 
6 months; disease recurrence or death; need for a second 
dose reduction; delay in schedule of 1 month or more; 
patient refusal to further treatment; or at the discretion of 
the attending physician.
Pretreatment and follow-up evaluation
Pretreatment evaluation included the patient’s medical 
history and physical examination, imaging tests using 
contrast-enhanced computed tomography or magnetic 
resonance imaging, blood tests, electrocardiogram and 
chest X-rays. Creatinine clearance was calculated using 
the Cockcroft-Gault formula. During treatment cycles, 
physical examination and blood tests were scheduled on 
each administration day of chemotherapy. Carcinoem-
bryonic antigen and carbohydrate antigen 19-9 (Ca19-9) 
were measured at the time patients were enrolled in the 
study and every month thereafter. Toxicity was evalu-
ated using the CTCae v4.0. all the safety data dur-
ing adjuvant therapy, even if it was off protocol, were 
included for analysis. Imaging tests were planned at 
every 12 weeks after the start of treatment, and additional 
imaging tests were performed to confirm recurrence if 
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clinically suspected. Treatment duration day was defined 




From July 2011 to July 2012, 18 patients from nine institu-
tions were enrolled (Table 1). Median age was 70.5 years 
(range 55–74). nine patients (50 %) had extrahepatic 
bile duct cancer, four (22 %) had gallbladder cancer, four 
(22 %) had ampullary cancer and one (6 %) had intra-
hepatic bile duct cancer. Pancreatoduodenectomy was 
performed in 12 patients (67 %), simple to a radical or 
extended cholecystectomy in 5 (28 %), and bile duct resec-
tion and partial hepatectomy in 3 (17 %). Median time of 
initiation of adjuvant therapy after surgical intervention 
was 49.7 days (range 29–72). Postoperative complications 
were seen in six patients (33 %). Fifteen patients (83 %) 
had a negative margin (r0) and three (17 %) had a micro-
scopically positive margin (r1).
DlT, MTD and rD
One DlT was observed in three patients at level 1 dur-
ing the first 6 weeks, namely grade 4 neutropenia. This 
dosage level was then expanded with three additional 
patients, and no further DlTs were observed. accord-
ing to the recommendation from the DSMC, a total of 18 
patients were enrolled at level 1 to thoroughly evaluate 
DlT and rD, then one patient who withdrew consent was 
excluded from evaluation of DlT. One DlT among 17 
patients was observed in level 1 during the first 6 weeks. 
Throughout the entire study, six (33 %) patients com-
pleted protocol treatment. eight (44 %) dropped out due 
to the need for a second dose reduction. Two did not meet 
starting criteria for creatinine with a grade 1 increase in 
CTCae v4.0. One had rapid tumor progression and died 
within 30 days after the last administration of GC. One 
withdrew consent.
Overall, we ensured the safety of level 1, the standard 
dose of the GC regimen, and defined it as the rD. MTD 
was not defined in this study because we did not plan to 
escalate the dosage of GC more than the standard dose.
Hematological adverse events
Overall, hematological toxic events were common, the 
most common of which was neutropenia (Table 2). Grade 
3–4 neutropenia, leucopenia, anemia and thrombocytopenia 
were observed in 56, 33, 0 and 6 % of patients during the 
first 6 weeks and in 94, 56, 22 and 6 % of patients through-
out the entire course of treatment, respectively. Febrile neu-
tropenia was not seen in this study.
non-hematological adverse events
Table 3 summarizes the non-hematological adverse events 
reported during the first 6 weeks and throughout the entire 
course of treatment according to CTCae v4.0. The major 
adverse events were anorexia, nausea, constipation and 
malaise. One patient developed pneumonia with grade 
1–2 neutropenia; he was admitted for treatment with an 
intravenous antibiotic and recovered well within 1 week. 
Throughout the entire treatment, two patients did not meet 
the starting criteria for creatinine, with a grade 1 increase 
in CTCae v4.0. Few grade 3–4 adverse events were 
observed, and all non-hematological toxic effects were 
manageable.
Treatment course
Treatment course is shown in Table 4. The planned duration 
of adjuvant GC was 6 months. Median and mean duration of 
Table 1  Baseline characteristics of patients (N = 18)
a
 Some are overlapping
Sex (M/F) 13/5





 ampulla of vater 4
resectability (r0/r1) 15/3




UICC-Stage 7th IB/IIa/IIB/III/IV 4/2/9/2/1
Postoperative complicationsa
 none 13
 Pancreatic fistula 4




 Bile duct resection 3
 Cholecystectomy 5
 Partial hepatectomy 3
Time of initiation of adjuvant therapy (days) (median, 
range)
49.7 (29–72)
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treatment was 142.5 (range 15–183) and 127 days, respec-
tively. Median number of GC administration was 10 times 
(range 1–16). Median and mean cumulative doses of gem-
citabine were 9,900 (range 1,000–15,000) and 9,289 mg/m2, 
respectively, while those of cisplatin were 250 (range 25–
400) and 244 mg/m2, respectively. eleven patients required 
a dose reduction in GC from level 1 to level 0.
Discussion
looking to improve the outcome of patients with BTC, we 
conducted a Phase I study of GC as adjuvant chemotherapy 
for BTC in patients undergoing curative resection without 
major hepatectomy. To the best of our knowledge, this is 
the first study which investigates the safety and feasibility 
of standard GC regimen as adjuvant setting for BTC.
Gemcitabine is rapidly metabolized to an inactive 
metabolite, 2′,2′-difluorodeoxyuridine by cytidine deami-
nase [15], which is expressed at varying levels in the 
human tissues [16], and the rapid clearance of gemcit-
abine can be attributed to its plentiful occurrence in the 
liver [17]. We were worried that a severe adverse event 
during adjuvant chemotherapy might occur after major 
hepatectomy and that patients would not tolerate standard 
GC therapy. Therefore, we excluded patients with BTC 
undergoing major hepatectomy on the basis of findings 
that patients with elevated bilirubin levels are at increased 
risk of hepatic injury with gemcitabine treatment [18] and 
that partially hepatectomized rats showed an increase in the 
area under the curve of cisplatin [19]. For the patients with 
BTC undergoing major hepatectomy, we are currently con-
ducting another Phase I trials which is expected to define 
the rD of gemcitabine or S-1, respectively.
With regard to the treatment of advanced BTC, the BT-
22 trial in Japan [14] showed a higher frequency of hemato-
logical adverse events during GC treatment than the aBC-
02 trial in the UK [13]. Particularly with the GC regimen, 
rates of grade 3–4 neutropenia, leucopenia, thrombocyto-
penia and anemia, respectively, were 56.1, 29.3, 39.0 and 
36.6 % in the BT-22 trial versus 25.3, 15.7 8.6, and 7.6 % 
in the aBC-02 trial. These differences in the frequency of 
hematological adverse events might have been due to eth-
nic differences. In this present adjuvant study, grade 3–4 
neutropenia and leucopenia were more common with rates 
of 56 and 33 % of cases during the first 6 weeks and 94 % 
and 56 % throughout the entire course of treatment. We 
experienced more frequent hematological adverse events 
compared to the BT-22 trial; however, we speculate that 
postoperative damage might be related to such adverse 
events. Despite these relatively severe hematological 
adverse events, only one patient suffered from pneumonia 
with grade 1–2 neutropenia, and all adverse events were 
manageable.
Table 2  Hematological adverse 
events
CTCAE common terminology 
criteria for adverse events
N = 18 First 6 weeks entire course
Grade (nCI-CTCae v4.0)1 2 3 4 Gr 3–4 (%) 1 2 3 4 Gr 3–4 (%)
neutropenia 1 6 9 1 56 0 1 13 4 94
leukopenia 4 6 6 0 33 2 6 10 0 56
anemia 8 5 0 0 0 5 8 4 0 22
Thrombocytopenia 6 3 1 0 6 6 4 0 1 6
Table 3  non-hematological 
adverse events
10 % or more frequent adverse 
events are listed in this table
N = 18 First 6 weeks entire course
Grade (nCI-CTCae v4.0) 1 2 3 4 Total (%) 1 2 3 4 Total (%)
Constipation 8 1 0 0 50 8 1 0 0 50
anorexia 4 4 0 0 44 6 3 1 0 56
nausea 4 3 0 0 39 5 4 0 0 50
Malaise 4 2 0 0 33 4 3 1 0 44
Vomiting 3 0 0 0 17 2 1 0 0 17
abd. pain 2 0 0 0 11 2 0 0 0 11
rash 2 0 0 0 11 3 0 0 0 17
Diarrhea 0 1 0 0 6 1 1 0 0 11
Stomatitis 1 0 0 0 6 4 0 0 0 22
Dysgeusia 1 0 0 0 6 4 0 0 0 22
alopecia 0 0 0 0 0 3 0 0 0 17
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although hematological adverse events with the stand-
ard dose of GC were more frequent in the adjuvant than in 
the advanced setting, the standard dose might nevertheless 
be feasible for adjuvant chemotherapy for BTC in patients 
undergoing curative resection without major hepatectomy. 
From this study, we have defined the standard dose of GC as 
the rD under careful observation. Because our present pro-
tocol required that patients needing a second dose reduction 
should be off protocol, eight of 18 patients (44 %) resulted 
in cessation of protocol treatment due to second dose reduc-
tion. However, now we are planning to start a subsequent 
phase II trial for patients in this setting, and the criteria for 
dose reduction should be revised to allow well-planned sec-
ond dose reduction, which would in turn allow more inten-
sive cumulative dosing with adjuvant GC. Furthermore, we 
have to pay more attention to patient care to prevent severe 
adverse events, and further clinical trials will be warranted 
to improve the outcome of patients with BTC.
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